A closer reading
How to read this page
Citicoline (CDP-choline) has been studied more than most supplements sold in the United States. That is unusual, and it cuts both ways. Many supplement ingredients have one small positive trial and nothing else. Citicoline has had large, serious trials, and two of the largest did not work. An honest evidence page has to show the negative results at least as clearly as the positive ones, because the negative ones come from the biggest and best-conducted studies.
A useful habit when reading this page is to ask three questions about any claim. How many people were studied? Was there a placebo group? And has the result been confirmed by a later, larger trial? Citicoline's story is, more than anything, a story about what happens when those questions get asked honestly.
For background on the molecule itself, see what citicoline is and CDP-choline and citicoline, they are the same compound under two names, and Cognizin is a brand of that same compound, not a different molecule.
Stroke: where the largest trial answered the question
Sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately.
Stroke is where citicoline's evidence record is most instructive. For years, the case for citicoline in acute ischaemic stroke rested on earlier pooled analyses, meta-analyses that combined the results of several smaller trials. Those analyses suggested a benefit, and they were the reason citicoline had a reputation in some countries as a stroke drug.
Then the ICTUS trial, published by Dávalos and colleagues in The Lancet in 2012, enrolled about 2,300 people with acute stroke and compared citicoline with placebo. It found no improvement in 90-day recovery. This was not a marginal result from a weak study. It was the largest trial of citicoline ever run in stroke, and it directly tested the claim the earlier analyses had supported.
What should a reader do with the conflict between the older meta-analyses and ICTUS? The general rule in evidence-based medicine is that a large, well-run trial outweighs a pooling of smaller, weaker ones. Smaller trials are more likely to be positive by chance, more likely to be published only when positive, and more likely to have design problems that inflate effects. When ICTUS failed to confirm the earlier signal, the honest conclusion was that the earlier signal was probably not real.
This does not mean citicoline is dangerous in stroke. It means it should not be presented as a stroke treatment. In the United States it is sold as a dietary supplement, not an FDA-approved drug, and it has no approved role in stroke care. Nothing about citicoline should ever delay standard emergency treatment.
Traumatic brain injury: a second large negative
The COBRIT trial, published by Zafonte and colleagues in JAMA in 2012, is the other anchor of citicoline's evidence base, and it points the same direction as ICTUS. In people with traumatic brain injury, citicoline did not improve functional or cognitive outcomes compared with placebo.
COBRIT matters for two reasons. First, it was large and rigorous, which makes its negative result hard to dismiss. Second, it undercuts a common marketing move: the idea that because citicoline is involved in cell membrane chemistry, it must help the brain heal after injury. That reasoning sounds plausible, but COBRIT tested it in real patients and it did not hold up.
If you or a family member is recovering from a brain injury, the evidence does not support citicoline as a way to speed or deepen that recovery. Recovery after brain injury is driven by rehabilitation, time, and medical care. A supplement with a negative large trial behind it should not displace any of those.
Memory and cognitive decline: a weaker but real signal
The picture is different, though still far from settled, in long-standing cognitive problems related to blood vessel disease in the brain.
A Cochrane review by Fioravanti and Yanagi looked at citicoline in chronic cerebrovascular cognitive decline. It found evidence suggesting a modest short-term benefit on memory and behaviour. Two caveats sit on top of that finding, and both matter. The trials in the review were short, so they say nothing about whether any benefit lasts. And they were of low quality by modern standards, which means their results should be read with caution.
The IDEALE study, reported by Cotroneo and colleagues, adds an observational data point. In people with mild vascular cognitive impairment, citicoline use was associated with stable cognitive scores, while an untreated group declined. That is an interesting result, but observational is not the same as proof. People who take a supplement differ from people who do not in all sorts of ways, health habits, medical attention, resources, that a study like this cannot fully separate from the supplement itself. IDEALE is a reason to study citicoline more in this setting, not a reason to call it a treatment.
For a closer look at this area, see citicoline and memory. The bottom line there is the same: suggestive, not established, and never a substitute for a medical workup of memory problems. New or worsening memory loss deserves a doctor's evaluation, because some causes are treatable.
Glaucoma: changed measurements, unproven outcomes
Small trials from the Parisi and Rossetti research groups have tested citicoline, by mouth or as eye drops, as an add-on in glaucoma. These trials found changes in electrophysiological measures, meaning tests of how the retina and visual pathway respond to stimulation.
That sounds encouraging, and it is why citicoline comes up in glaucoma discussions. But there is a gap between a changed measurement and a preserved eyesight. Whether citicoline slows actual vision loss in glaucoma has not been established. Glaucoma care rests on lowering eye pressure under an ophthalmologist's supervision, and nothing about these small trials changes that. See citicoline and glaucoma for more.
Attention in healthy people: small, positive, industry-funded
Two small trials by McGlade and colleagues tested citicoline's effects on attention in healthy people. In a 2012 study, women taking 250 or 500 mg scored better on attention tests. A separate study in adolescent males found gains in attention and psychomotor speed. Both were funded by the maker of Cognizin, the branded form of citicoline.
Industry funding does not make a study worthless, but it is a reason to want independent confirmation, which does not yet exist. Small positive trials in healthy people also answer a narrow question: short-term test performance, not school or work outcomes, and not any clinical condition. These results are real but preliminary, and they should not be stretched into claims about treating attention disorders.
ADHD: the claim with no evidence behind it
Citicoline is sometimes marketed for ADHD, usually by borrowing credibility from the healthy-attention trials above. That borrowing is not justified. There are no adequate trials of citicoline for ADHD. There is no good evidence citicoline treats ADHD. The adolescent attention study measured test performance in healthy volunteers, not symptoms in people with an ADHD diagnosis. ADHD is a clinical condition with proven treatments, and delaying those treatments in favour of an unproven supplement carries real cost. See citicoline and ADHD.
What mechanism can and cannot tell you
You will often see citicoline's mechanism used as an argument for buying it. The evidence does suggest that citicoline supports membrane phospholipid synthesis, the building and repair of cell membranes. Neuroprotective effects, however, have been shown only in preclinical work: laboratory and animal studies, not patient outcomes.
The stroke and brain injury trials show why this distinction matters. The mechanism was plausible. The preclinical data were encouraging. And when large trials asked the only question that counts, do patients do better?, the answer in acute stroke and traumatic brain injury was no. Mechanism is a hypothesis generator, not a result.
Safety and practical questions
Across trials, citicoline was generally well tolerated at doses from 250 to 2,000 mg per day. Reported side effects were mostly mild: stomach upset, headache, and insomnia. Data in pregnancy and breastfeeding are lacking, so use in those situations cannot be called safe. One interaction is worth flagging: citicoline may enhance the effects of levodopa, so people with Parkinson's disease should involve their neurologist before taking it.
For detail, see citicoline side effects and doses used in studies. Good questions to raise with a clinician are collected at questions to ask your doctor.
A fair summary
The citicoline evidence is neither a success story nor a fraud. The largest trials in acute stroke (ICTUS) and traumatic brain injury (COBRIT) found no benefit over placebo, and those results deserve the most weight. A Cochrane review suggests a modest short-term benefit in chronic cerebrovascular cognitive decline, but on short, low-quality trials. The glaucoma work changed measurements without proving preserved vision. The attention trials were small and industry-funded. ADHD has no adequate evidence at all.
Anyone weighing a purchase should read how to choose a citicoline supplement with this record in mind: the strongest claims about citicoline are exactly the ones the strongest trials did not support.
